Abu-Ghanem Y, et al. - A scrutiny was conducted of the upshot of perioperative blood transfusion (PBT) on the prognosis of patients who underwent nephrectomy as a result of renal cell carcinoma (RCC). The data shed light on the connection between PBT with reduced recurrence-free survival, cancer-specific survival (CSS), disease-free survival, and overall survival (OS) in the study cohort. The independent assessment for patients undergoing partial nephrectomy (PN) revealed worse oncological outcomes.

Methods

• The eligible candidates comprised of 1,159 patients who underwent radical nephrectomy or partial nephrectomy (PN) between the years 1987 and 2013.
• Univariate and multivariate models inspected the link between PBT with cancer-specific survival (CSS), disease-free survival, and overall survival (OS).

Results

• 198 patients (17.1%) received a PBT, among 1,159 patients undergoing nephrectomy.
• The median follow-up was 63.2 months.
• Lower preoperative hemoglobin (P<0.01), size of the renal mass (P<0.05), open surgical approach (P<0.01), and capsular invasion were the risk factors for PBT.
• Receipt of a PBT displayed a connection with prominently adverse disease-free survival (hazard ratio [HR] = 2.1, P = 0.02), metastatic progression (HR = 2.4, P = 0.007), CSS (HR = 2.5, P = 0.02), and OS (HR = 2.2, P = 0.001).
• 582 patients underwent PN. 87 (14.9%) patients among these required PBT.
• The tie-up of PBT with outcome was vital in this subgroup after controlling for patient and tumor-related variables with respect to metastatic progression (HR = 5.9, P = 0.006), CSS (HR = 5.8, P = 0.007) and OS (HR = 2.1, P = 0.05).